Investor & Analyst Meeting Z

RNS Number : 8400Z
Smith & Nephew Plc
29 September 2009
 



Smith & Nephew Investor and Analyst Meeting


29 September 2009


Smith & Nephew plc (LSE: SN, NYSE: SNN), the global medical technology business, will be holding an institutional investor and analyst meeting in ZurichSwitzerland on 19 and 20 November 2009.


The event will be hosted by David Illingworth, Chief Executive and Adrian Hennah, Chief Financial Officer.  The purpose of the visit is to provide an opportunity to more fully understand the strategy and operations of Smith & Nephew's business units in Europe and the Emerging Marketsas well as meet some of our senior management.


Presentations will be made between 12 noon and 2.30pm GMT (7am and 9.30am Easternon Thursday 19 November and between 7am and 11.30pm GMT (2am and 6.30am Eastern) on Friday 20 November 2009.  The presentations at the event will be webcast live on Smith & Nephew's corporate website at www.smith-nephew.com.  An archive of these presentations will be available on the website shortly after the end of the meeting.



Enquiries:


Investors/Analysts


Hannah Longbottom

Tel: +44 (0) 20 7401 7646

Corporate Affairs Manager


Smith & Nephew plc




Media


Jon Coles

Brunswick - London

+44 (0) 20 7404 5959



Cindy Leggett-Flynn 

Brunswick - New York

+1 (212) 333 3810



About Us


Smith & Nephew is a global medical technology business, specialising in Orthopaedics, including Reconstruction, Trauma and Clinical Therapies; Endoscopy and Advanced Wound Management. Smith & Nephew is a global leader in arthroscopy and advanced wound management and is one of the leading global orthopaedics companies. 


Smith & Nephew is dedicated to helping improve people's lives. The Company prides itself on the strength of its relationships with its surgeons and professional healthcare customers, with whom its name is synonymous with high standards of performance, innovation and trust. The Company operates in 32 countries around the world. Annual sales in 2008 were $3.8 billion.


Forward-Looking Statements


This press release contains certain 'forward-looking statements' within the meaning of the US Private Securities Litigation Reform Act of 1995. In particular, statements regarding expected revenue growth and trading margins discussed under 'Outlook' are forward-looking statements as are discussions of our product pipeline. These statements, as well as the phrases 'aim', 'plan', 'intend', 'anticipate', 'well-placed', 'believe', 'estimate', 'expect', 'target', 'consider' and similar expressions, are generally intended to identify forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors (including, but not limited to, the outcome of litigation, claims and regulatory approvals) that could cause the actual results, performance or achievements of Smith & Nephew, or industry results, to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20F, for a discussion of certain of these factors.


All forward-looking statements in this press release are based on information available to Smith & Nephew as of the date hereof. All written or oral forward-looking statements attributable to Smith & Nephew or any person acting on behalf of Smith & Nephew are expressly qualified in their entirety by the foregoing. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement contained herein to reflect any change in Smith & Nephew's expectation with regard thereto or any change in events, conditions or circumstances on which any such statement is based.



This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCCKCKDCBKKPCB
UK 100

Latest directors dealings